In spite of current improvement of clinical outcome offered by antibody-based targeted therapies, such as VEGF targeted therapies, ccRCC still suffers from high cancer-related deaths annually, which requires more powerful strategies to improve patient survival outcomes. Here, VEGFA is linked to cancer.